Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
04 February 2009 - 2:19AM
PR Newswire (US)
- New clinical development offices further Covance's geographic
reach, expand access to patients - PRINCETON, N.J., Feb. 3
/PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the
world's largest and most comprehensive drug development services
companies, today announced the opening of three new clinical
development offices in Kiev, Ukraine; Bratislava, Slovakia; and Tel
Aviv, Israel to further enhance the company's global presence.
Covance has been providing clinical trial support in Central and
Eastern Europe since 1994, with offices in Poland, Hungary, The
Czech Republic, Bulgaria, Romania, and Russia. The new offices
located in Kiev and Bratislava will support staff in Ukraine and
Slovakia, including Covance's regional network of field-based CRAs
throughout Central and Eastern Europe and the former Soviet Union.
Covance has been providing clinical trial support in South-Eastern
Europe (Greece and Turkey) and the Middle East (Israel and Egypt),
with Israel being a strategic location since 1995. The new Tel Aviv
office serves to center operations and support staff across both
regions. "The establishment of this series of three new offices
indicates our commitment to serve the needs of our clients for
high-quality and timely clinical development on a global basis,
leveraging the patient and investigator potential of emerging
markets," said Robert J. Davie, PhD, vice president and general
manager, clinical development services Europe, Covance. "We will
continue moving forward with our strategy to expand into
geographies that align our therapeutic focus with investigators
that consistently demonstrate high-quality results, regulatory
compliance, and enrollment performance to meet the current and
future clinical research needs of our clients." The new offices and
expanded staff will help Covance expedite the execution of clinical
studies and build strategic relationships with investigators and
sites in countries well known for their excellent potential to
contribute to global clinical trial conduct. Covance offers
clinical development services, including Phase I, II and III
clinical trial support in more than 55 countries which include
emerging markets across Central and Eastern Europe, Asia Pacific
and Latin America. With a full-suite of services to take a drug
through all stages of drug development, Covance offers extensive
clinical and therapeutic expertise, global reach, proactive project
management, and strong investigator site relationships to
consistently deliver high quality data on time. About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the
world's largest and most comprehensive drug development services
companies with annual revenues greater than $1.5 billion, global
operations in more than 20 countries, and more than 9,600 employees
worldwide. Information on Covance's products and services, recent
press releases, and SEC filings can be obtained through its website
at http://www.covance.com/. Statements contained in this press
release, which are not historical facts, are forward-looking
statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding
anticipated trends in the Company's business are based largely on
management's expectations and are subject to and qualified by risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation,
competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the
Company's ability to continue to attract and retain qualified
personnel, the fixed price nature of contracts or the loss of large
contracts, and other factors described in the Company's filings
with the Securities and Exchange Commission. DATASOURCE: Covance
Inc. CONTACT: Media Relations, +1-609-419-2466, or Investor
Relations, +1-609-452-4807, both for Covance Web Site:
http://www.covance.com/
Copyright